Objective To examine the efficacy and safety of pegloticase in combination with methotrexate
(MTX) in patients with uncontrolled gout in an exploratory, open-label clinical trial (…

Objective To assess efficacy, safety, pharmacokinetics, and immunogenicity of pegloticase
plus methotrexate (MTX) versus pegloticase plus placebo cotreatment for uncontrolled gout in …

Objective To assess 12‐month safety and efficacy of pegloticase + methotrexate (MTX)
versus pegloticase + placebo (PBO) cotherapy in a PBO‐controlled, double‐blind trial (A …

Background Uncontrolled/refractory gout patients are recalcitrant/intolerant to oral urate-lowering
therapies (ULTs), experiencing frequent gout flares, functionally limiting tophi, and low …

Background Publications suggest immunomodulation co-therapy improves responder rates
in uncontrolled/refractory gout patients undergoing pegloticase treatment. The MIRROR open…

OBJECTIVE To compare fenofibric acid (FA) + statin to respective monotherapies on the
prevalence of metabolic syndrome and its diagnostic components in patients with mixed …

Background: In an open-label, single-arm trial in adult patients with uncontrolled gout (MIRROR
open-label [OL] trial) evaluating pegloticase co-treatment with methotrexate (MTX); 78.6…

Background Patients (pts) with gout refractory to oral urate-lowering therapy (ULT) have few
treatment options. Pegloticase (pegylated uricase) lowers serum uric acid (sUA) in these pts, …

Background Gout affects more than 9 million Americans, 1 with some suffering so severely
that everyday life becomes painful and difficult. Pegloticase is an infused uricase-based …

Background: Gout development follows persistent serum uric acid (sUA) elevation. Patients
who are refractory to or cannot tolerate oral urate lowering therapies (ULTs) have limited …